Rheumatology International

, Volume 31, Issue 12, pp 1545–1547

Methotrexate for rheumatoid arthritis patients who are on hemodialysis

Review Article

DOI: 10.1007/s00296-011-2041-5

Cite this article as:
Al-Hasani, H. & Roussou, E. Rheumatol Int (2011) 31: 1545. doi:10.1007/s00296-011-2041-5

Abstract

Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.

Keywords

Methotrexate Rheumatoid arthritis Hemodialysis End stage renal failure 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Barts and The London School of Medicine and DentistryLondonUK
  2. 2.Department of Rheumatology and RehabilitationKing George HospitalIlfordUK
  3. 3.Barking Havering and Redbridge University Hospitals NHS TrustKing George HospitalIlfordUK

Personalised recommendations